Abstract
Overexpression of chemokine receptor type 4 (CXCR4) has been found to be associated with increased cell proliferation, metastasis and also act as an indicator of poor prognosis in patients with breast cancer. Therefore, new agents that can abrogate CXCR4 expression have potential against breast cancer metastasis. In this study, we examined the potential effect of thymoquinone (TQ), derived from the seeds of Nigella sativa, on the expression and regulation of CXCR4 in breast cancer cells. TQ was found to inhibit the expression of CXCR4 in MDA-MB-231 triple negative breast cancer (TNBC) cells in a dose- and time-dependent manner. It was noted that suppression of CXCR4 by TQ was possibly transcriptionally regulated, as treatment with this drug caused down-regulation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activation and suppression of NF-κB binding to the CXCR4 promoter. Pretreatment with a proteasome inhibitor and/or lysosomal stabilization did not affect TQ induced suppression of CXCR4. Down-regulation of CXCR4 was further correlated with the inhibition of CXCL12-mediated migration and invasion of MDA-MB-231 cells. Interestingly, it was observed that the deletion of p65 could reverse the observed anti-invasive/anti-migratory effects of TQ in breast cancer cells. TQ also dose-dependently inhibited MDA-MB-231 tumor growth and tumor vascularity in a chick chorioallantoic membrane assay model. We also observed TQ (2 and 4 mg/kg) treatment significantly suppressed multiple lung, brain, and bone metastases in a dose-dependent manner in a metastasis breast cancer mouse model. Interestingly, H&E and immunohistochemical analysis of bone isolated from TQ treated mice indicated a reduction in number of osteolytic lesions and the expression of metastatic biomarkers. In conclusion, the results indicate that TQ primarily exerts its anti-metastatic effects by down-regulation of NF-κB regulated CXCR4 expression and thus has potential for the treatment of breast cancer.
Introduction
Breast cancer is the second most common cancer that afflicts women, with an estimated 1.67 million women diagnosed with breast cancer in 2012 (Bray et al., 2012; Torre et al., 2015). Breast cancer ranked fifth in cancer-associated deaths among all cancers globally in 2012 (Bray et al., 2012; Torre et al., 2015). While incredible development has been made for the treatment of breast cancers, the treatment of triple negative breast cancer (TNBC) is quite a challenge owing to its destructive features and limited treatment options (Jia et al., 2016; Wang et al., 2018). Often, chemotherapy for breast cancer is ridden with side effects and drug resistance, leading to failure in therapy. Compelling evidence suggests that if breast cancer metastasis to distant site organs can be prevented, then it is an indicator for good prognostic outcome (Alvarez et al., 2010; Perez and Spano, 2012). Interactions between chemokines and their cognate receptors play important roles in tumor metastasis. The interaction between chemokine receptor type 4 (CXCR4) and its cognate ligand stromal-derived factor-1 (SDF1 or CXCL12) plays a crucial role in the regulation of migration and metastasis in a variety of solid tumors including breast cancer (Balkwill, 2004a,b). Moreover, SDF1 has been found to be frequently over-expressed in lymph nodes, lung, liver, and bone marrow (Muller et al., 2001; Keeley et al., 2010). Hence, in the present study, we investigated the effect of thymoquinone on the SDF1/CXCR4 signaling axis.
Numerous novel bioactive compounds have been reported in several parts of medicinal plants that play an essential role in the prevention and treatment of chronic inflammation driven cancers (Shanmugam et al., 2011a, 2012, 2015, 2016; Sethi et al., 2012; Yang et al., 2013; Tang et al., 2014; Bishayee and Sethi, 2016; Hasanpourghadi et al., 2017). Thymoquinone (TQ) is one of the volatile bioactive constituents of Nigella sativa seed oil. Various studies have reported the anti-inflammatory, anti-oxidant, and anti-cancer properties of TQ both in vitro and in vivo (Shanmugam et al., 2018). TQ has been found to inhibit breast, ovarian, pancreatic, colon adenocarcinoma (Worthen et al., 1998; Shoieb et al., 2003; Gali-Muhtasib et al., 2004; Woo et al., 2012, 2013), human osteosarcoma (Roepke et al., 2007), lung carcinoma (Kaseb et al., 2007), myeloblastic leukemia (El-Mahdy et al., 2005), and multiple myeloma (Li et al., 2010; Siveen et al., 2014b) by modulation of diverse molecular targets that are involved in cell proliferation, survival, invasion, metastasis, and angiogenesis. In vivo TQ has been reported to inhibit the growth of tumors (Salem, 2005; Gali-Muhtasib et al., 2006; Woo et al., 2013). Moreover, TQ has been found to down-regulate inducible nitric oxide synthase and cyclooxygenase-2 (COX-2) (El-Mahmoudy et al., 2002; El Mezayen et al., 2006).
The master transcription factor nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) plays a pivotal role in the development and progression of inflammation-driven diseases including cancer (Dey et al., 2008; Sethi et al., 2008b, 2012; Sethi and Tergaonkar, 2009; Shanmugam et al., 2013; Li et al., 2015; Liu et al., 2018; Puar et al., 2018). In human chronic myeloid leukemia cells (KBM-5), TQ was reported to abrogate NF-κB activation and augment cellular apoptosis (Sethi et al., 2008a). Several other studies have shown that TQ can also down-regulate protein kinase B and extracellular receptor kinase signaling pathways (Yi et al., 2008). Woo et al., 2011 reported that TQ can exert a strong anti-proliferative effects in TNBC cells by activating peroxisome proliferator-activated receptor gamma (PPARγ) (Woo et al., 2011). TQ administered intraperitoneally, has been found to be well tolerated up to 22.5 mg/kg in male rats and 15 mg/kg in female rats; whereas for TQ administered orally, the dose was as high as 250 mg/kg in both male and female rats (Abukhader, 2012).
Our prior published data has already indicated that TQ can exert anti-cancer effects on MCF7 breast cancer cells through activation of the PPARγ signaling cascade (Woo et al., 2011). In a recent study TQ was shown to suppresses the proliferation, migration, and invasion of metastatic MDA-MB-321 breast cancer cells by inhibiting the p38 mitogen-activated protein kinase pathway in vitro and in vivo (Woo et al., 2013). Therefore, we postulated that TQ may modulate the expression of CXCR4 and inhibit tumor metastasis in vivo. Our results indicate that TQ can down-regulate CXCR4 expression and CXCL12-induced migration and invasion in breast cancer cell lines through inhibition of NF-κB activation. Furthermore, we tried to investigate the effect of TQ on experimental metastasis that involved the injection of breast cancer cells directly into the systemic circulation (Hwang et al., 2015).
Breast cancer has a greater tendency to spread to the bone marrow of the femora, tibiae, and the mandibular bones. Therefore, intracardiac injection method has been employed to develop osteolytic bone metastasis model (van der Horst and van der Pluijm, 2012; Kumar and Manjunatha, 2013; Lee et al., 2014). On the basis of the crucial role of SDF1/CXCR4 in breast cancer metastasis to femora, tibiae, and mandibles, we systemically injected via an intracardiac route MDA-MB-231-luc+ cells to test the ability of TQ to modulate CXCR4 expression and thereby inhibit metastasis to the bones and other organs.
Materials and Methods
Cell Lines
Human breast cancer MCF7, MDA-MB-231, and BT-549 were purchased from ATCC (Manassas, VA, United States). The MDA-MB-231-luciferase expressing cell line was purchased from Cell Biolabs, United States. The cells were cultured in DMEM supplemented with 10% fetal bovine serum (FBS) and antibiotics penicillin/streptomycin.
Materials
Thymoquinone (TQ), N-Acetyl-L-leucyl-L-leucyl-L-norleucinal (ALLN), chloroquine, formic acid, Tris, glycine, NaCl, sodium dodecyl sulfate (SDS), crystal violet, and bovine serum albumin were purchased from Sigma-Aldrich (St. Louis, MO, United States). A 50 mM solution of TQ was prepared with dimethyl sulfoxide (DMSO) and stored as small aliquots at -20°C. RPMI 1640, FBS, antibiotic-antimycotic mixture, and lipofectamine were obtained from Invitrogen (Carlsbad, CA, United States). Antibody against CXCR4 (polyclonal) was obtained both from Abcam (Cambridge, MA, United States) and Santa Cruz Biotechnology (Santa Cruz, CA, United States). CXCL12 was purchased from ProSpec-Tany TechnoGene, Ltd. (Rehovot, Israel). Antibody against β-actin (monoclonal), control siRNA and p65 siRNA was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, United States). Ki-67 polyclonal antibody, Lamin B1, phospho-p65 (Ser 536), and p65 monoclonal antibodies were obtained from Cell Signaling Technology (Beverly, MA, United States). Goat anti-rabbit-horseradish peroxidase (HRP) conjugate and goat anti-mouse HRP were purchased from Sigma-Aldrich (St. Louis, MO, United States). D-Luciferin Firefly potassium salt was purchased from Gold Biotechnology, United States. Formic acid was purchased from Sigma-Aldrich (St. Louis, MO, United States). The NF-κB luciferase plasmid was obtained from Stratagene (La Jolla, CA, United States). The Bradford protein assay reagent was purchased from Bio-Rad Laboratories (Hercules, CA, United States). Isoflurane for anesthesia was purchased from National University of Singapore, Animal holding unit pharmacy (Singapore).
Western Blotting
Vehicle or TQ-treated breast cancer cell lines and tumor tissues obtained from the mouse study were lysed in RIPA lysis buffer (Li et al., 2010). Nuclear extracts of TQ treated or control cells were prepared using TransAM nuclear extract kit according to the manufacturer’s instructions. Whole cell lysates was resolved on a 10% SDS polyacrylamide gel electrophoresis (SDS–PAGE) gel. The proteins were electro-transferred to a nitrocellulose membrane (Bio-Rad), blocked with Blocking One (Nacalai Tesque, Inc.), and probed with antibodies of interest overnight at 4°C. The blot was washed with tris-buffered saline with 0.1% Tween-20, exposed to HRP-conjugated secondary antibodies for 1 h, and finally examined by chemiluminescence using Western Bright Sirius HRP substrate (Advansta). Images were captured using a ChemiDoc XRS+ imaging system and analyzed using Image LabTM software (Bio-Rad, Hercules, CA, United States) as described previously (Chua et al., 2010). Densitometric analysis was done using ImageJ software.
NF-κB Reporter Assay
MDA-MB-231 and BT-549 cells were plated in 6-well plates with 1 × 104 cells per well in complete medium. The following morning, cells were transfected with an NF-κB reporter plasmid linked to a luciferase gene or with the dominant-negative IκBα (IκBα-DN) plasmid, co-transfected with a β-galactosidase plasmid (Promega, Madison, WI, United States). Transfections were done according to the manufacturer’s protocols using Lipofectamine (Invitrogen, United States). At 24 h post-transfection, cells were treated with TQ (50 μM) for indicated time points and then washed and lysed in luciferase lysis buffer (Promega). Luciferase activity was measured using a Tecan plate reader (Durham, NC, United States) by using a luciferase assay kit (Promega) and was normalized to β-galactosidase activity. All luciferase experiments were done in triplicate as previously described (Shanmugam et al., 2011b).
NF-κB DNA-Binding Activity Assay
To determine NF-κB activation, nuclear extracts were prepared using a nuclear extraction kit (Active Motif, Carlsbad, CA, United States) according to the manufacturer’s instructions. NF-κB DNA-binding activity was analyzed using the TransAM NF-κB p65 transcription factor assay kit (Active Motif, Carlsbad, CA, United States), following the manufacturer’s instructions. The enzymatic product was measured at 450 nm with a microplate reader (Tecan Systems, San Jose, CA, United States) as previously described (Shanmugam et al., 2011b).
Chromatin Immunoprecipitation and Quantitative RT-PCR
Human MDA-MB 231 and BT-549 TNBC cells were seeded in 15-cm culture dishes and treated with TQ (50 μM) for 0, 2, 4, 6, and 8 h. At the end of the treatment period the cells were fixed with 1% formaldehyde at room temperature for 10 min and neutralized with glycine. The cells were collected, resuspended in CHIP lysis buffer, and sonicated (Vibra-Cell,TM Newtown, CT, United States). Samples were incubated with protein-G beads that had been pre-incubated with 4–10 μg of anti-NF-κB antibody (Cell Signaling Technology, MA, United States) or negative control IgG (Sigma-Aldrich Co., St. Louis, MO, United States). The next day, immunoprecipitants were washed by using washing buffer and reverse cross-linked at 65°C. The DNA was then purified by using a PCR purification kit purchased from MACHEREY-NAGEL (Duren, Germany). Finally, the purified DNA was subjected to quantitative RT-PCR and data analyzed.
Scratch Wound Healing Assay
MDA-MB-231 and BT-549 cells were seeded in culture plate containing a culture-insert (Ibidi, Martinsried, Germany) until fully confluent. A cell-free gap of 500 μm was created after removing the culture-insert. After incubation with 50 μM TQ for 12 h, the medium was changed to medium with or without CXCL12. After migration for 8 or 24 h, the wound distance was observed and captured using bright field microscopy and the gap distance was measured using Photoshop software (Manu et al., 2011; Shanmugam et al., 2011b,c). MDA-MB-231 cells were transfected with 50 nmol/L of p65 or control siRNA. The cells were then subjected to wound healing assay either in the presence or absence of TQ (50 uM) for 8 h.
Invasion Assay
An in vitro cell invasion assay was performed using a BioCoat Matrigel invasion assay system (BD Biosciences, San Jose, CA, United States), as described previously (Manu et al., 2013; Shanmugam et al., 2011b,c). MDA-MB-231 cells were transfected with 50 nmol/L of p65 or control siRNA. The cells were then subjected to invasion assay either in the presence or absence of TQ (50 uM) for 8 h.
Determination of Tumor Growth Using a Chick Choriallantoic Membrane Assay
The chick chorioallantoic membrane (CAM) assay was modified from Sys et al. (2013). Briefly, fertilized chicken eggs (Bovans Goldline Brown) were purchased from Chew’s Agriculture Pte Ltd., Singapore and placed horizontally in a 37.5°C incubator with 70% humidity on embryonic day (ED)-0. On ED-3, a sharp weighted tool was used to poke a hole at the apex of the eggshell, and 3 mL of albumin was removed using a 5 mL syringe and 18G needle in order to drop the CAM. The sharp weighted tool was then used to poke a hole in the middle of the egg before using curved surgical scissors to cut a 1 cm2 hole. The eggs were screened and dead embryos were removed. The hole was then sealed with a 1624W Tegaderm semi-permeable membrane and the egg placed back into the incubator. On ED-7, MDA-MB-231 (0.65 × 106) cells were mixed with matrigel. Fifty micro liter of the matrigel-cell mixture was placed on the CAM/egg. The hole was then re-sealed with the Tegaderm semi-permeable membrane. Twenty micro liter of DMSO or 25, 50, or 100 μM of TQ was added by pipetting onto autoclaved filter paper disks on ED-10 after the initial ultrasound scan. The tumor volume and tumor vascularity was determined at the 72 h time point in the control and TQ treated groups.
Ultrasound Imaging
On embryonic day 10, and after 72 h incubation with or without TQ, the Tegaderm membrane was removed and Aquasonic gel was added onto cling wrap that had been carefully placed over the CAM tumors. Using a VisualSonics Vevo 2100 Imaging system, a 550D transducer connected to a 3D acquisition monitor was used to obtain ultrasound images of the tumors formed on the CAM. Parallel 2D sections obtained were further reconstructed to form 3D images of the tumors. Tumor volumes and percentage of vasculature were calculated using the Vevo Lab 1.7.0 program. On ED-13, after ultrasound imaging, the CAM tumors, along with chick liver (to check for metastasis) were carefully excised and washed in PBS, part of it was snap frozen in liquid nitrogen for molecular analysis while the other part was fixed in 10% formalin overnight at 4°C, before being embedded in paraffin. The paraffin blocks were then taken for future histopathological analysis.
Intracardiac Experimental Metastasis Murine Model
All procedures involving animals were reviewed and approved by the NUS Institutional Animal Care and Use Committee. Seven week old NCr-Foxn1nu, female mice were purchased from InVivos Pte Ltd., Singapore. NCr-Foxn1nu female mice were intracardially implanted with 1 × 106 MDA-MB-231-luc+ cell line. Female nude mice (age 7 weeks) were anesthetized with 3–5% isoflurane. On day 0, anesthetized animals were injected with 1 × 106 MDA-MB-231-luc+ cells suspended in 100 μl sterile Dulbecco phosphate buffered saline (DPBS) into the left ventricle of the heart by non-surgical means (Contag et al., 2000). D-Luciferin potassium salt (Gold Biotechnology, St. Louis, MO, United States) at room temperature was dissolved in DPBS without calcium or magnesium to a final concentration of 15 mg/ml. The luciferin solution was sterilized using a 0.22 micron filter and then injected intraperitoneally at a concentration of 150 mg/kg body weight (b.w). The mice were placed in an imaging chamber and imaged both on the dorsal and ventral sides whilst under isoflurane anesthesia (3–5%) using an IVISTM Imaging System (Xenogen Corporation, United States), for 20 s–3 min as described previously (Rehemtulla et al., 2000; Jenkins et al., 2003a,b; Scatena et al., 2004).
A successful intracardiac injection was indicated on day 0 by images showing systemic bioluminescence distributed throughout the animal. Only mice indicating a satisfactory injection were included in the experimental groups. The mice were imaged once every week for tumor cell metastasis for a total of 4 weeks. Generally, two to three mice were imaged at a time. Imaging and quantification of signals were controlled by the acquisition and analysis software Living Image® (Xenogen® Corporation, United States). Tissues of interest were excised, placed into 24-well tissue culture plates with 300 μg/ml D-luciferin in DPBS and imaged for 1–2 min. Tissues were subsequently fixed in 10% formalin (Sigma, St. Louis, MO, United States) and prepared for standard histopathology evaluation.
Hematoxylin and Eosin Staining
At the end of treatment, mice hind limbs and fore limbs were collected and fixed in 10% neutral buffered formalin solution (Sigma-Aldrich, St. Louis, MO, United States). The limbs’ muscle tissue was then removed to expose the bone. The bones were then decalcified by soaking in citric acid buffered formic acid (Sigma-Aldrich, St. Louis, MO, United States) for 96 h. The softened and decalcified bone was then processed and embedded into paraffin wax blocks. The bone samples were then sectioned and stained with hematoxylin and eosin solution (Merck, Germany). Images were taken using an Olympus BX51 microscope (magnification, 40×).
Immunohistochemical (IHC) Analysis of Tumor Samples
Breast cancer tumor cells that had metastasized to the bone, lung, and brain from control and drug-treated groups were fixed with 10% phosphate buffered formalin, processed, and embedded in paraffin. The bone and tumor sections, 5 μM in thickness, were cut and deparaffinized in xylene, dehydrated in graded ethanols, and finally hydrated in water. Antigen retrieval was conducted by boiling the slide in 10 mM sodium citrate (pH 6.0) for 30 min. Sections were incubated overnight with anti-CXCR4 primary antibody (1:100 dilutions). IHC was conducted following the manufacturer’s instructions (Dako LSAB Kit) as described previously (Dai et al., 2015; Zhang et al., 2016). Images were taken using an Olympus BX51 microscope (magnification, 40×). Quantitative analysis of IHC images was performed by visual scores between the control and treated images. In this expression quantitation technique, each image was divided into four parts and each part was individually quantitated for the biomarker expression. A cell scored as positive refers simply to the presence of brown staining (peroxidase) in any part of the studied tissue. A negative cell scored refers to no staining or weak staining.
Statistical Analysis
Student t-test was used to analyze the data. For in vivo studies, unpaired t-test was used for statistical comparisons between groups. p < 0.05 was considered statistically significant (GraphPad Prism 5.0; GraphPad Software, CA, United States).
Results
The present study was designed to investigate the effect of TQ (with structure shown in Figure 1A) on both CXCR4 expression and function in BT-549 and MDA-MB-231 TNBC cells and in a metastatic murine model.
FIGURE 1
TQ Suppresses CXCR4 Protein Expression in Breast Cancer Cells
We first studied the effect of TQ on the expression of CXCR4 in MCF7 and MDA-MB-231 breast cancer cell lines. We observed that TQ could suppress the expression of CXCR4 in a dose- and time-dependent manner in MCF7 (Figures 1B,C, left panel) and MDA-MB-231 (Figures 1B,C, right panel), respectively.
Down-Regulation of CXCR4 Expression by TQ Is Not Mediated Through Its Degradation
Previous studies have shown that CXCR4 undergoes ubiquitination at its lysine residue, followed by degradation (Kukreja et al., 2005; Shanmugam et al., 2011b); hence, we next examined the likelihood that TQ may augment the rate of CXCR4 degradation through the stimulation of proteasomes. MDA-MB-231 and BT-549 cells were pretreated with ALLN, a proteasome inhibitor, for 1 h before treating with TQ. As shown in Figure 1D, ALLN did not protect TQ-induced degradation of CXCR4, thereby indication that this is an improbable basis for the downregulation of CXCR4 expression by TQ. In addition we also studied the capability of chloroquine, a lysosomal inhibitor, to abrogate TQ-induced degradation of CXCR4, as CXCR4 has been shown to undergo ligand-dependent lysosomal degradation (Shanmugam et al., 2011b). Both the cell lines were pretreated with chloroquine for 1 h before being treated with TQ. Our results indicated that chloroquine at 200 μM only marginally prevented the degradation of CXCR4 (Figure 1E), thereby suggesting that this was possibly not the main pathway for suppression of expression of CXCR4.
TQ Modulates Constitutive Activation of NF-κB in TNBC Cells
The NF-κB pro-survival signaling pathway plays a critical role in breast cancer cell progression and metastasis (Helbig et al., 2003). The promoter region of the CXCR4 gene also has several NF-κB binding sites (Shanmugam et al., 2011b). Therefore it is possible that TQ suppresses NF-κB activation and downregulate CXCR4 expression. We found that treatment with TQ suppressed NF-κB activation in a time-dependent manner (Figure 2A). This result suggests that TQ may down-regulate CXCR4 expression through inhibition of NF-κB activation. However, DNA binding alone is not always associated with NF-κB -dependent gene transcription, suggesting that added controlling steps are involved. Subsequent results also indicated that TQ inhibited NF-κB reporter activity in a time-dependent manner in TNBC cells (Figure 2B). As both phosphorylation and nuclear translocation are critical for the function of transcription factors, we next evaluated the effect of TQ on nuclear translocation of p65 and phospho-p65 expression by Western blot analysis. We found that TQ dose-dependently suppressed nuclear accumulation of p65 and phospho-p65 expression in the nucleus of MDA-MB-231 cells (Figure 2E).
FIGURE 2
TQ Abrogates CXCL12-Induced Over-Expression of CXCR4
Chemokine receptor type 4 is one of the most important chemokine receptors in TNBC. High CXCR4 expressing tumor cells have a greater invasive and metastatic potential, and CXCR4+ cells migrate following a concentration gradient of CXCL12. Overexpression of this receptor has been observed in patients who exhibit advanced stages of cancer and metastasis and correlates with worse prognosis and decreased patient survival (Kato et al., 2003). We next investigated if indeed TQ can suppress CXCL12 induced overexpression of CXCR4 in MDA-MB-231 cells. Interestingly, we found that TQ suppressed CXCL12 induced over-expression of CXCR4 in MDA-MB-231 cells thereby indicating that positive feedback loop between CXCR4 and downstream signaling components may be mediated in an autocrine manner (Figure 2F).
TQ Attenuates NF-κB Transcriptional Activity by Decreasing Its Binding to the CXCR4 Promoter
Whether the down-regulation of CXCR4 by TQ in TNBC cells was due to suppression of NF-κB activation in vivo was examined by a ChIP assay targeting NF-κB binding in the CXCR4 promoter. We found that TQ suppressed NF-κB binding to the CXCR4 promoter (Figures 2C,D) in both the TNBC cell lines, thereby indicating that TQ inhibits CXCR4 expression by suppressing NF-κB binding to the CXCR4 promoter. According to the quantitative RT-PCR result, compared to the untreated samples, TQ significantly decreased the binding of NF-κB to the CXCR4 promoter and this reduction was noted to occur in a time-dependent fashion (Figures 2C,D).
TQ Inhibits CXCL12-Induced Cellular Invasion and Migration
We further elucidated the effect on TQ on CXCL12-induced cell invasion. Using an in vitro invasion assay, TQ treatment suppressed CXCL12-induced invasion in both the cell lines (Figures 3A,B). Furthermore, we performed addition experiment by using p65 siRNA to inhibit the NF-κB signaling pathway and to determine the anti-invasive potential of TQ on MDA-MB-231 cells. Interestingly, we found that upon inhibition of NF-κB, TQ was not able to significantly mitigate cellular invasion (Figure 3E). Whether the down-regulation of CXCR4 by TQ correlates with cell migration was also examined using an in vitro scratch wound healing assay. We found that both MDA-MB-231 and BT-549 cells migrated faster under the influence of CXCL12 and this effect was abolished on treatment with TQ (Figures 3C,D). Interestingly, we found that upon inhibition of NF-κB using p65 siRNA, TQ was not able to significantly attenuate cellular migration (Figure 3F).
FIGURE 3
TQ Abolishes Tumor Growth and Vascular Volume in a CAM Assay Model
We evaluated the effect of TQ on the growth of tumors in a CAM assay model. We found that 3D ultrasound scanning of tumors indicated that TQ could inhibit the growth of tumors in a dose-dependent manner. TQ at doses of 50 and 100 μM significantly inhibited the growth of tumors compared to the vehicle control group (Figure 4B), and potently reduced the tumor vascular volume at doses of 50 and 100 μM, thereby indicating complete abrogation of tumor vasculature by TQ (Figure 4C). However, TQ at the lower dose of 25 μM had no effect on tumor growth and vascularity. Photographic images of CAM vehicle treated and TQ treated CAM tumors are shown in Figure 4A.
FIGURE 4
TQ Inhibits Breast Cancer Bone Metastasis and Thinning of Bones
To investigate whether TQ can suppress bone metastasis, 8 weeks old nude mice were injected intracardiac with MDA-MB-231-luc+ expressing cells and then treated with TQ 2 mg or 4 mg/kg b.w. intraperitoneally for 4 weeks. The mice were divided into three groups and the schematic of the TQ dosing regimen is shown in Figure 5B. Bioluminescence images showed a decrease in number of colonies metastasized to distant site organs compared to vehicle control animals (Figure 5A). A significant dose-dependent, anti-metastatic effect was observed in the lung tissue (Figure 5C) and in the brain tissue (Figure 5D). High CXCR4 expressing MDA-MB-231 cells always tend to move to a region rich in CXCL12 such as bone marrow (Fernandis et al., 2004; Hung et al., 2014). By the third and fourth week we detected bone metastasis. At 4 weeks, metastatic activity was greater in control mice compared to TQ treated mice (Figure 5E).
FIGURE 5
Remarkably, it was found that TQ significantly suppressed the metastasis of breast cancer cells to the bone (Figure 5E), and also there was a decrease in the metastatic sites such as bone marrow of the femora, tibiae, and mandibles. We observed a decrease in metastatic osteolytic lesions using H&E staining, and a significant decrease in the bone colonization of breast cancer cells (Figure 6B). A similar anti-metastatic effect was also observed in the lung (Figure 5C) and brain tissues (Figure 5D). In addition, no significant decrease in the body weight was observed both in the vehicle treated control and TQ treatment group (data not shown). H&E examination of the bone sections revealed prevention of thinning of bones in the TQ treated group as compared to control mice (Figure 6B).
FIGURE 6
TQ Reduces the Expression of NF-κB Regulated Gene Products in the Tumor Tissues
NF-κB regulates the expression of several genes that are involved in tumor growth, metastasis, and angiogenesis (Li et al., 2015). A dose-dependent decrease in the expression of NF-κB-regulated proteins (CXCR4 and Ki-67) in the lung and brain tissues was observed by immunoblot analysis (Figure 6A). As shown in Figure 6C, TQ treatment inhibited CXCR4 expression in bone (top panel), lung (middle panel), and brain tissues (bottom panel), that was assessed by IHC analysis. A marked decrease in the expression of CXCR4 was observed in the femur of mice, and a similar effect was observed in the lung and brain tissues treated with TQ (4 mg/kg b.w.).
Discussion
The current study was designed to investigate the anti-metastatic effect of TQ, and its underlying molecular mechanisms of action in TNBC cell lines in vitro and in an intracardiac metastatic murine model. CXCR4 over-expression has been associated with tumor cell proliferation, invasion, and metastasis. TQ was found to inhibit the expression of CXCR4 in MDA-MB-231 and MCF7 breast cancer cell lines, irrespective of the cell type and HER2 status. We further observed that TQ inhibited constitutive NF-κB DNA binding and activation in both the TNBC cell lines and significantly suppressed NF-κB dependent luciferase expression. These results are in line with previous work showing that TQ can abrogate NF-κB activation pathway (Sethi et al., 2008a; Siveen et al., 2014b) in diverse cells. Interestingly, TQ mediated down-regulation of CXCR4 did not occur by proteolytic degradation of the receptor but rather by a decrease in the number of transcripts. In addition, inhibition of the CXCR4 receptor was associated with down-regulation of migration and invasion of TNBC cells upon stimulation with its ligand CXCL12. Numerous reports have previously suggested that CXCR4 is over-expressed in a variety of tumors including gastric, ovarian, pancreatic, melanoma, renal, cervical, colon, and hematological malignancies (Manu et al., 2011, 2013; Shanmugam et al., 2011b). However, there are no substantial studies elaborating upon the detailed mechanism(s) of CXCR4 over-expression in tumor cells (Kulbe et al., 2005).
Genetic mutations in von Hippel Lindau tumor suppressor gene (Staller et al., 2003), PAX3- and PAX7-FKHR gene fusion (Libura et al., 2002), angiogenic growth factors (Bachelder et al., 2002; Schioppa et al., 2003), deregulated NF-κB (Zlotnik, 2006), and pro-inflammatory cytokines (Kulbe et al., 2005) have all been implicated in CXCR4 over-expression. Recent evidence implicates that EGFR, c-erbB2 and its encoding gene HER2/neu, can also regulate CXCR4 expression at the post-transcriptional level in breast cancer cells (Benovic and Marchese, 2004; Arya et al., 2007). Moreover, studies have implicated CXCR4 over-expression to cancer metastasis and are an indicator of poor prognosis and overall patient survival (Xu et al., 2015). A high level of expression of CXCR4 was significantly associated with a greater risk of bone metastasis. Bone metastasis occurs significantly more often in CXCR4 positive patients (13.1%) as compared to CXCR4 negative patients (2.4%; P = 0.008) (Hung et al., 2014). In a recent article, Ashour et al. (2014, 2016) demonstrated that TQ can also inhibit NF-κB phosphorylation and its regulated gene products, such as interleukin-8 and chemokines, in a dose- and time-dependent manner in hepatocellular carcinoma cells. Therefore, CXCR4 appears to be a novel therapeutic target for the treatment of metastatic breast cancer. It has also been suggested that CXCR4 may be degraded by ligand-dependent lysosomal degradation (Fernandis et al., 2004) and by atrophin-interacting protein 4 mediated polyubiquitination and subsequent degradation (Bhandari et al., 2007).
CXCL12 is the only ligand for CXCR4 and acts as autocrine/paracrine growth factor for several cancers. Interestingly, we found that CXCL12 was able to increase the levels of CXCR4 in TNBC cells. In a recent study, it has been reported that the overexpression of both CXCR4 and CXCL12 mRNA in glioblastoma cancer stem cells (GBM-CSC) can control proliferation, invasion and angiogenesis. CXCL12 secretion from CXCR4 expressing cells supports the occurrence of autocrine/paracrine mechanism in GBM CSCs, in human meningioma and pituitary adenoma cells (Gatti et al., 2013). Furthermore, in another study by Borrello et al. (2005), it was reported that transforming oncogene RET/PTC1 in human papillary thyroid carcinoma can induce the expression of CXCL12 and its receptor CXCR4, thus triggering autocrine proliferation of thyroid carcinoma cells (Borrello et al., 2005). Our results also demonstrate that TQ can substantially suppress CXCR4 expression in TNBC cells and this modulation was observed to occur at the transcriptional level and not mediated by either ligand-dependent lysosomal or proteasomal degradation. Because TQ was observed to modulate inhibit both NF-κB DNA binding and reporter gene expression, we further investigated the effects of TQ on CXCL12-induced invasion and migration in TNBC cell lines. We found that pre-incubation with TQ completely blocked CXCL12-induced migration and invasive potential of TNBC cells. Furthermore, TQ failed to abrogate inhibit invasion or migration of cells in p65 deleted cells.
We also investigated for the first time the potential effect of TQ on breast cancer cell bone metastasis in a breast cancer mouse model. CXCL12 signaling via CXCR4 has an important physiological role in hematopoietic stem cell homing to the bone marrow (Balkwill, 2004b; Xu et al., 2015). This signaling axis also plays a critical part in breast cancer cell metastasis by increasing chemotaxis to regions of high CXCL12 expression such as bone, lung, and brain (Arya et al., 2007). Therefore, down-regulation of CXCR4 in triple negative metastatic breast cancer cells could greatly decrease their metastatic potential. In our study we also determined the anti-cancer effects in a tumor-bearing chick embryo model. The CAM assay has been used extensively as a model for studying angiogenesis due to the accessibility and visibility of the developing blood vessels (Siveen et al., 2014a). However, recent studies have shown that tumor cells can grow readily on the CAM in an immunocompromised environment (Sys et al., 2013).
Tumor bearing chick embryos have been used to study anti-cancer effects of drugs (Abe et al., 2011; Busch et al., 2013). In our study, we implanted breast cancer cells onto the CAM and evaluated the effects of TQ on tumor growth and vascularity. We found that TQ dose-dependently inhibited tumor growth and potently reduced the tumor vascular volume. Furthermore, we found that intraperitoneal administration of TQ at doses of 2 or 4 mg/kg b.w for 4 weeks could inhibit the growth and metastasis of breast cancer tumors. TQ significantly suppressed lung, bone, and brain metastasis, as evidenced by a decrease in bioluminescence signals in these organs. It is of note that patients with terminal breast cancer exhibit severe bone destruction associated with osteolytic lesions (Mundy, 2002). We further evaluated the inhibitory effect of TQ on osteolytic bone metastasis in nude mice inoculated with MDA-MB-231-luc+ cells into the left cardiac ventricle. Bone metastasis was found to be significantly suppressed in the TQ treated group, and the number of osteolytic lesions in the mandibles, femora, and tibiae were markedly decreased, as indicated by bioluminescence imaging. Western blot analysis of tumors obtained from the lung and brain also showed a decrease in the expression of CXCR4 and Ki67. In fact, upon TQ treatment, there was a marked reduction in thinning of bones, as evidenced by H&E staining. In addition, IHC analysis of lung, brain, and bone tumors revealed inhibition of CXCR4 expression. Overall, TQ was well tolerated at the doses tested and was effective in suppressing the metastasis of TNBC cells. In conclusion, TQ inhibited NF-κB regulated CXCR4 expression, migration, as well as invasion of the TNBC cells, and markedly suppressed bone metastasis by suppressing NF-κB activation cascade. Further studies are warranted as TQ as its clinically relevant doses are yet to be determined.
Statements
Author contributions
GS, APK, KHBT, LL, RH, KSA, AC, TA, MS, and SA conceived the project. GS, APK, KHBT, LL, RH, and KSA designed the experiments. MS, AH, CW, YY, and APK carried out the experiments and analysis the data. MS, GS, AKo, APK, KSA, and FA wrote and corrected the paper.
Funding
This work was supported by NUHS basic seed grant to KHBT. APK was supported by grants from National Medical Research Council of Singapore, NCIS Yong Siew Yoon Research Grant through donations from the Yong Loo Lin Trust. APK and RH were also supported by the National Research Foundation Singapore and the Singapore Ministry of Education under its Research Centers of Excellence initiative to Cancer Science Institute of Singapore, National University of Singapore.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AbeC.UtoY.NakaeT.ShinmotoY.SanoK.NakataH.et al (2011). Evaluation of the in vivo radiosensitizing activity of etanidazole using tumor-bearing chick embryo.J. Radiat. Res.52208–214. 10.1269/jrr.10122
2
AbukhaderM. M. (2012). The effect of route of administration in thymoquinone toxicity in male and female rats.Indian J. Pharm. Sci.74195–200. 10.4103/0250-474X.106060
3
AlvarezR. H.ValeroV.HortobagyiG. N. (2010). Emerging targeted therapies for breast cancer.J. Clin. Oncol.283366–3379. 10.1200/JCO.2009.25.4011
4
AryaM.AhmedH.SilhiN.WilliamsonM.PatelH. R. (2007). Clinical importance and therapeutic implications of the pivotal CXCL12-CXCR4 (chemokine ligand-receptor) interaction in cancer cell migration.Tumour Biol.28123–131. 10.1159/000102979
5
AshourA. E.Abd-AllahA. R.KorashyH. M.AttiaS. M.AlzahraniA. Z.SaquibQ.et al (2014). Thymoquinone suppression of the human hepatocellular carcinoma cell growth involves inhibition of IL-8 expression, elevated levels of TRAIL receptors, oxidative stress and apoptosis.Mol. Cell. Biochem.38985–98. 10.1007/s11010-013-1930-1
6
AshourA. E.AhmedA. F.KumarA.ZoheirK. M.Aboul-SoudM. A.AhmadS. F.et al (2016). Thymoquinone inhibits growth of human medulloblastoma cells by inducing oxidative stress and caspase-dependent apoptosis while suppressing NF-kappaB signaling and IL-8 expression.Mol. Cell. Biochem.416141–155. 10.1007/s11010-016-2703-4
7
BachelderR. E.WendtM. A.MercurioA. M. (2002). Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4.Cancer Res.157203–7206.
8
BalkwillF. (2004a). Cancer and the chemokine network.Nat. Rev. Cancer4540–550. 10.1038/nrc1388
9
BalkwillF. (2004b). The significance of cancer cell expression of the chemokine receptor CXCR4.Semin. Cancer Biol.14171–179.
10
BenovicJ. L.MarcheseA. (2004). A new key in breast cancer metastasis.Cancer Cell6429–430. 10.1016/j.ccr.2004.10.017
11
BhandariD.TrejoJ.BenovicJ. L.MarcheseA. (2007). Arrestin-2 interacts with the ubiquitin-protein isopeptide ligase atrophin-interacting protein 4 and mediates endosomal sorting of the chemokine receptor CXCR4.J. Biol. Chem.28236971–36979. 10.1074/jbc.M705085200
12
BishayeeA.SethiG. (2016). Bioactive natural products in cancer prevention and therapy: progress and promise.Semin. Cancer Biol.40–41, 1–3. 10.1016/j.semcancer.2016.08.006
13
BorrelloM. G.AlbertiL.FischerA.Degl’innocentiD.FerrarioC.GariboldiM.et al (2005). Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene.Proc. Natl. Acad. Sci. U.S.A.10214825–14830. 10.1073/pnas.0503039102
14
BrayF.JemalA.GreyN.FerlayJ.FormanD. (2012). Global cancer transitions according to the human development index (2008-2030): a population-based study.Lancet Oncol.13790–801. 10.1016/S1470-2045(12)70211-5
15
BuschC.KrochmannJ.DrewsU. (2013). The chick embryo as an experimental system for melanoma cell invasion.PLoS One8:e53970. 10.1371/journal.pone.0053970
16
ChuaA. W.HayH. S.RajendranP.ShanmugamM. K.LiF.BistP.et al (2010). Butein downregulates chemokine receptor CXCR4 expression and function through suppression of NF-kappaB activation in breast and pancreatic tumor cells.Biochem. Pharmacol.801553–1562. 10.1016/j.bcp.2010.07.045
17
ContagC. H.JenkinsD.ContagP. R.NegrinR. S. (2000). Use of reporter genes for optical measurements of neoplastic disease in vivo.Neoplasia241–52. 10.1038/sj.neo.7900079
18
DaiX.AhnK. S.KimC.SiveenK. S.OngT. H.ShanmugamM. K.et al (2015). Ascochlorin, an isoprenoid antibiotic inhibits growth and invasion of hepatocellular carcinoma by targeting STAT3 signaling cascade through the induction of PIAS3.Mol. Oncol.9818–833. 10.1016/j.molonc.2014.12.008
19
DeyA.WongE.KuaN.TeoH. L.TergaonkarV.LaneD. (2008). Hexamethylene bisacetamide (HMBA) simultaneously targets AKT and MAPK pathway and represses NF kappaB activity: implications for cancer therapy.Cell Cycle.73759–3767. 10.4161/cc.7.23.7213
20
El MezayenR.El GazzarM.NicollsM. R.MareckiJ. C.DreskinS. C.NomiyamaH. (2006). Effect of thymoquinone on cyclooxygenase expression and prostaglandin production in a mouse model of allergic airway inflammation.Immunol. Lett.10672–81. 10.1016/j.imlet.2006.04.012
21
El-MahdyM. A.ZhuQ.WangQ. E.WaniG.WaniA. A. (2005). Thymoquinone induces apoptosis through activation of caspase-8 and mitochondrial events in p53-null myeloblastic leukemia HL-60 cells.Int. J. Cancer117409–417. 10.1002/ijc.21205
22
El-MahmoudyA.MatsuyamaH.BorganM. A.ShimizuY.El-SayedM. G.MinamotoN.et al (2002). Thymoquinone suppresses expression of inducible nitric oxide synthase in rat macrophages.Int. Immunopharmacol.21603–1611. 10.1016/S1567-5769(02)00139-X
23
FernandisA. Z.PrasadA.BandH.KloselR.GanjuR. K. (2004). Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells.Oncogene23157–167. 10.1038/sj.onc.1206910
24
Gali-MuhtasibH.Diab-AssafM.BoltzeC.Al-HmairaJ.HartigR.RoessnerA.et al (2004). Thymoquinone extracted from black seed triggers apoptotic cell death in human colorectal cancer cells via a p53-dependent mechanism.Int. J. Oncol.25857–866.
25
Gali-MuhtasibH.RoessnerA.Schneider-StockR. (2006). Thymoquinone: a promising anti-cancer drug from natural sources.Int. J. Biochem. Cell Biol.381249–1253. 10.1016/j.biocel.2005.10.009
26
GattiM.PattarozziA.BajettoA.WurthR.DagaA.FiaschiP.et al (2013). Inhibition of CXCL12/CXCR4 autocrine/paracrine loop reduces viability of human glioblastoma stem-like cells affecting self-renewal activity.Toxicology314209–220. 10.1016/j.tox.2013.10.003
27
HasanpourghadiM.LooiC. Y.PanduranganA. K.SethiG.WongW. F.MustafaM. R. (2017). Phytometabolites targeting the warburg effect in cancer cells: a mechanistic review.Curr. Drug Targets181086–1094. 10.2174/1389450117666160401124842
28
HelbigG.ChristophersonK. W.Bhat-NakshatriP.KumarS.KishimotoH.MillerK. D.et al (2003). NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4.J. Biol. Chem.27821631–21638. 10.1074/jbc.M300609200
29
HungC. S.SuH. Y.LiangH. H.LaiC. W.ChangY. C.HoY. S.et al (2014). High-level expression of CXCR4 in breast cancer is associated with early distant and bone metastases.Tumour Biol.351581–1588. 10.1007/s13277-013-1218-9
30
HwangY. S.HanS. S.KimK. R.Ye-JinL.Sun-KyungL.Kwang-KyunP.et al (2015). Validating of the pre-clinical mouse model for metastatic breast cancer to the mandible.J. Appl. Oral. Sci.233–8. 10.1590/1678-775720140158
31
JenkinsD. E.OeiY.HornigY. S.YuS. F.DusichJ.PurchioT.et al (2003a). Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis.Clin. Exp. Metastasis20733–744.
32
JenkinsD. E.YuS. F.HornigY. S.PurchioT.ContagP. R. (2003b). In vivo monitoring of tumor relapse and metastasis using bioluminescent PC-3M-luc-C6 cells in murine models of human prostate cancer.Clin. Exp. Metastasis20745–756.
33
JiaL. Y.ShanmugamM. K.SethiG.BishayeeA. (2016). Potential role of targeted therapies in the treatment of triple-negative breast cancer.Anticancer Drugs27147–155. 10.1097/CAD.0000000000000328
34
KasebA. O.ChinnakannuK.ChenD.SivanandamA.TejwaniS.MenonM.et al (2007). Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer.Cancer Res.677782–7788. 10.1158/0008-5472.CAN-07-1483
35
KatoM.KitayamaJ.KazamaS.NagawaH. (2003). Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma.Breast Cancer Res.5R144–R150. 10.1186/bcr627
36
KeeleyE. C.MehradB.StrieterR. M. (2010). CXC chemokines in cancer angiogenesis and metastases.Adv. Cancer Res.10691–111. 10.1016/S0065-230X(10)06003-3
37
KukrejaP.Abdel-MageedA. B.MondalD.LiuK.AgrawalK. C. (2005). Up-regulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1alpha (CXCL12) increases endothelial adhesion and transendothelial migration: role of MEK/ERK signaling pathway-dependent NF-kappaB activation.Cancer Res.659891–9898. 10.1158/0008-5472.CAN-05-1293
38
KulbeH.HagemannT.SzlosarekP. W.BalkwillF. R.WilsonJ. L. (2005). The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells.Cancer Res.6510355–10362. 10.1158/0008-5472.CAN-05-0957
39
KumarG.ManjunathaB. (2013). Metastatic tumors to the jaws and oral cavity.J. Oral. Maxillofac Pathol.1771–75. 10.4103/0973-029X.110737
40
LeeJ. H.KimB.JinW. J.KimJ. W.KimH. H.HaH.et al (2014). Trolox inhibits osteolytic bone metastasis of breast cancer through both PGE2-dependent and independent mechanisms.Biochem. Pharmacol.9151–60. 10.1016/j.bcp.2014.06.005
41
LiF.RajendranP.SethiG. (2010). Thymoquinone inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells through suppression of signal transducer and activator of transcription 3 activation pathway.Br. J. Pharmacol.161541–554. 10.1111/j.1476-5381.2010.00874.x
42
LiF.ZhangJ.ArfusoF.ChinnathambiA.ZayedM. E.AlharbiS. A.et al (2015). NF-kappaB in cancer therapy.Arch. Toxicol.89711–731. 10.1007/s00204-015-1470-4
43
LiburaJ.DrukalaJ.MajkaM.TomescuO.NavenotJ. M.KuciaM.et al (2002). CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion.Blood1002597–2606. 10.1182/blood-2002-01-0031
44
LiuL.AhnK. S.ShanmugamM. K.WangH.ShenH.ArfusoF.et al (2018). Oleuropein induces apoptosis via abrogating NF-kappaB activation cascade in estrogen receptor-negative breast cancer cells.J. Cell. Biochem.10.1002/jcb.27738[Epub ahead of print].
45
ManuK. A.ShanmugamM. K.OngT. H.SubramaniamA.SiveenK. S.PerumalE.et al (2013). Emodin suppresses migration and invasion through the modulation of CXCR4 expression in an orthotopic model of human hepatocellular carcinoma.PLoS One8:e57015. 10.1371/journal.pone.0057015
46
ManuK. A.ShanmugamM. K.RajendranP.LiF.RamachandranL.HayH. S.et al (2011). Plumbagin inhibits invasion and migration of breast and gastric cancer cells by downregulating the expression of chemokine receptor CXCR4.Mol. Cancer10:107. 10.1186/1476-4598-10-107
47
MullerA.HomeyB.SotoH.GeN.CatronD.BuchananM. E.et al (2001). Involvement of chemokine receptors in breast cancer metastasis.Nature41050–56. 10.1038/35065016
48
MundyG. R. (2002). Metastasis to bone: causes, consequences and therapeutic opportunities.Nat. Rev. Cancer2584–593. 10.1038/nrc867
49
PerezE. A.SpanoJ. P. (2012). Current and emerging targeted therapies for metastatic breast cancer.Cancer1183014–3025. 10.1002/cncr.26356
50
PuarY. R.ShanmugamM. K.FanL.ArfusoF.SethiG.TergaonkarV. (2018). Evidence for the involvement of the master transcription factor NF-kappaB in cancer initiation and progression.Biomedicines27:6. 10.3390/biomedicines6030082
51
RehemtullaA.StegmanL. D.CardozoS. J.GuptaS.HallD. E.ContagC. H.et al (2000). Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging.Neoplasia2491–495. 10.1038/sj.neo.7900121
52
RoepkeM.DiestelA.BajboujK.WalluscheckD.SchonfeldP.RoessnerA.et al (2007). Lack of p53 augments thymoquinone-induced apoptosis and caspase activation in human osteosarcoma cells.Cancer Biol. Ther.6160–169. 10.4161/cbt.6.2.3575
53
SalemM. L. (2005). Immunomodulatory and therapeutic properties of the Nigella sativa L. seed.Int. Immunopharmacol.51749–1770. 10.1016/j.intimp.2005.06.008
54
ScatenaC. D.HepnerM. A.OeiY. A.DusichJ. M.YuS. F.PurchioT.et al (2004). Imaging of bioluminescent LNCaP-luc-M6 tumors: a new animal model for the study of metastatic human prostate cancer.Prostate59292–303. 10.1002/pros.20003
55
SchioppaT.UranchimegB.SaccaniA.BiswasS. K.DoniA.RapisardaA.et al (2003). Regulation of the chemokine receptor CXCR4 by hypoxia.J. Exp. Med.1981391–1402. 10.1084/jem.20030267
56
SethiG.AhnK. S.AggarwalB. B. (2008a). Targeting nuclear factor-kappa B activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis.Mol. Cancer Res.61059–1070. 10.1158/1541-7786.MCR-07-2088
57
SethiG.ShanmugamM. K.RamachandranL.KumarA. P.TergaonkarV. (2012). Multifaceted link between cancer and inflammation.Biosci. Rep.321–15. 10.1042/BSR20100136
58
SethiG.SungB.AggarwalB. B. (2008b). Nuclear factor-kappaB activation: from bench to bedside.Exp. Biol. Med.23321–31.
59
SethiG.TergaonkarV. (2009). Potential pharmacological control of the NF-kappaB pathway.Trends Pharmacol. Sci.30313–321. 10.1016/j.tips.2009.03.004
60
ShanmugamM. K.ArfusoF.KumarA. P.WangL.GohB. C.AhnK. S.et al (2018). Modulation of diverse oncogenic transcription factors by thymoquinone, an essential oil compound isolated from the seeds of Nigella sativa Linn.Pharmacol. Res.129357–364. 10.1016/j.phrs.2017.11.023
61
ShanmugamM. K.KannaiyanR.SethiG. (2011a). Targeting cell signaling and apoptotic pathways by dietary agents: role in the prevention and treatment of cancer.Nutr. Cancer63161–173. 10.1080/01635581.2011.523502
62
ShanmugamM. K.ManuK. A.OngT. H.RamachandranL.SuranaR.BistP.et al (2011b). Inhibition of CXCR4/CXCL12 signaling axis by ursolic acid leads to suppression of metastasis in transgenic adenocarcinoma of mouse prostate model.Int. J. Cancer1291552–1563. 10.1002/ijc.26120
63
ShanmugamM. K.RajendranP.LiF.NemaT.ValiS.AbbasiT.et al (2011c). Ursolic acid inhibits multiple cell survival pathways leading to suppression of growth of prostate cancer xenograft in nude mice.J. Mol. Med.89713–727. 10.1007/s00109-011-0746-2
64
ShanmugamM. K.KumarA. P.TanB. K. H.SethiG. (2013). Role of NF-κB in tumorigenesis.For. Immunopathol. Dis. Ther.4187–203. 10.1615/ForumImmunDisTher.2013008382
65
ShanmugamM. K.LeeJ. H.ChaiE. Z.KanchiM. M.KarS.ArfusoF.et al (2016). Cancer prevention and therapy through the modulation of transcription factors by bioactive natural compounds.Semin. Cancer Biol.40–4135–47. 10.1016/j.semcancer.2016.03.005
66
ShanmugamM. K.NguyenA. H.KumarA. P.TanB. K.SethiG. (2012). Targeted inhibition of tumor proliferation, survival, and metastasis by pentacyclic triterpenoids: potential role in prevention and therapy of cancer.Cancer Lett.320158–170. 10.1016/j.canlet.2012.02.037
67
ShanmugamM. K.RaneG.KanchiM. M.ArfusoF.ChinnathambiA.ZayedM. E.et al (2015). The multifaceted role of curcumin in cancer prevention and treatment.Molecules202728–2769. 10.3390/molecules20022728
68
ShoiebA. M.ElgayyarM.DudrickP. S.BellJ. L.TithofP. K. (2003). In vitro inhibition of growth and induction of apoptosis in cancer cell lines by thymoquinone.Int. J. Oncol.22107–113. 10.3892/ijo.22.1.107
69
SiveenK. S.AhnK. S.OngT. H.ShanmugamM. K.LiF.YapW. N.et al (2014a). Y-tocotrienol inhibits angiogenesis-dependent growth of human hepatocellular carcinoma through abrogation of AKT/mTOR pathway in an orthotopic mouse model.Oncotarget51897–1911.
70
SiveenK. S.MustafaN.LiF.KannaiyanR.AhnK. S.KumarA. P.et al (2014b). Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-kappaB regulated gene products in multiple myeloma xenograft mouse model.Oncotarget5634–648.
71
StallerP.SulitkovaJ.LisztwanJ.MochH.OakeleyE. J.KrekW. (2003). Chemokine receptor CXCR4 downregulated by von hippel-lindau tumour suppressor pVHL.Nature425307–311. 10.1038/nature01874
72
SysG. M.LapeireL.StevensN.FavoreelH.ForsythR.BrackeM.et al (2013). The in ovo CAM-assay as a xenograft model for sarcoma.J. Vis. Exp.17:e50522. 10.3791/50522
73
TangC. H.SethiG.KuoP. L. (2014). Novel medicines and strategies in cancer treatment and prevention.Biomed. Res. Int.2014:474078. 10.1155/2014/474078
74
TorreL. A.BrayF.SiegelR. L.FerlayJ.Lortet-TieulentJ.JemalA. (2015). Global cancer statistics, 2012.CA Cancer J. Clin.6587–108. 10.3322/caac.21262
75
van der HorstG.van der PluijmG. (2012). Preclinical models that illuminate the bone metastasis cascade.Recent Results Cancer Res.1921–31. 10.1007/978-3-642-21892-7_1
76
WangC.KarS.LaiX.CaiW.ArfusoF.SethiG.et al (2018). Triple negative breast cancer in Asia: an insider’s view.Cancer Treat. Rev.6229–38. 10.1016/j.ctrv.2017.10.014
77
WooC. C.HsuA.KumarA. P.SethiG.TanK. H. (2013). Thymoquinone inhibits tumor growth and induces apoptosis in a breast cancer xenograft mouse model: the role of p38 MAPK and ROS.PLoS One8:e75356. 10.1371/journal.pone.0075356
78
WooC. C.KumarA. P.SethiG.TanK. H. (2012). Thymoquinone: potential cure for inflammatory disorders and cancer.Biochem. Pharmacol.83443–451. 10.1016/j.bcp.2011.09.029
79
WooC. C.LooS. Y.GeeV.YapC. W.SethiG.KumarA. P.et al (2011). Anticancer activity of thymoquinone in breast cancer cells: possible involvement of PPAR-gamma pathway.Biochem. Pharmacol.82464–475. 10.1016/j.bcp.2011.05.030
80
WorthenD. R.GhoshehO. A.CrooksP. A. (1998). The in vitro anti-tumor activity of some crude and purified components of blackseed, Nigella sativa L.Anticancer Res.181527–1532.
81
XuC.ZhaoH.ChenH.YaoQ. (2015). CXCR4 in breast cancer: oncogenic role and therapeutic targeting.Drug Des. Dev. Ther.94953–4964. 10.2147/DDDT.S84932
82
YangS. F.WengC. J.SethiG.HuD. N. (2013). Natural bioactives and phytochemicals serve in cancer treatment and prevention.Evid. Based Comp. Alternat. Med.2013:698190. 10.1155/2013/698190
83
YiT.ChoS. G.YiZ.PangX.RodriguezM.WangY.et al (2008). Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways.Mol. Cancer Ther.71789–1796. 10.1158/1535-7163.MCT-08-0124
84
ZhangJ.AhnK. S.KimC.ShanmugamM. K.SiveenK. S.ArfusoF.et al (2016). Nimbolide-induced oxidative stress abrogates STAT3 signaling cascade and inhibits tumor growth in transgenic adenocarcinoma of mouse prostate model.Antioxid. Redox Signal.24575–589. 10.1089/ars.2015.6418
85
ZlotnikA. (2006). Chemokines and cancer.Int. J. Cancer1192026–2029. 10.1002/ijc.22024
Summary
Keywords
breast cancer, metastasis, thymoquinone, chemokine receptor 4, preclinical “in vivo” study
Citation
Shanmugam MK, Ahn KS, Hsu A, Woo CC, Yuan Y, Tan KHB, Chinnathambi A, Alahmadi TA, Alharbi SA, Koh APF, Arfuso F, Huang RY-J, Lim LHK, Sethi G and Kumar AP (2018) Thymoquinone Inhibits Bone Metastasis of Breast Cancer Cells Through Abrogation of the CXCR4 Signaling Axis. Front. Pharmacol. 9:1294. doi: 10.3389/fphar.2018.01294
Received
22 June 2018
Accepted
22 October 2018
Published
04 December 2018
Volume
9 - 2018
Edited by
Velia D’Agata, Università degli Studi di Catania, Italy
Reviewed by
Lushen Li, University of Maryland, Baltimore, United States; Cornelis F. M. Sier, Leiden University, Netherlands
Updates
Copyright
© 2018 Shanmugam, Ahn, Hsu, Woo, Yuan, Tan, Chinnathambi, Alahmadi, Alharbi, Koh, Arfuso, Huang, Lim, Sethi and Kumar.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Gautam Sethi, phcgs@nus.edu.sg Alan Prem Kumar, csiapk@nus.edu.sg
†These authors have contributed equally to this work
This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.